United States Brain Cancer Treatment Market in 2025 | Novel Drug Launches, R&D Investments & Growth Forecast - Novartis AG, Pfizer Inc, F.Hoffmann La Roche Ltd, Y-mAbS Therapeutics, Inc

DataM Intelligence has published a new research report on "Brain Cancer Treatment Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

American Medical Association (AMA) reports that by 2050, over 20% of the world's population will be aged 65 or older.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/brain-cancer-treatment-market?kb

Latest M&A Activity

Jazz Pharmaceuticals completed its acquisition of Chimerix, gaining access to dordaviprone, a promising drug candidate for diffuse intrinsic pontine glioma and other aggressive brain cancers. This deal aligns with Jazz's strategy to expand oncology portfolios with rare disease assets.​

Merck KGaA expanded its rare cancer footprint by acquiring SpringWorks Therapeutics for $3.9 billion, including programs addressing glioma brain cancers with promising MEK inhibitors.​

Lyell Immunopharma acquired ImmPACT Bio, bolstering its CAR T-cell therapy pipeline in brain tumor immunotherapy.

Key Players:

Novartis AG, Pfizer Inc, F.Hoffmann La Roche Ltd, Y-mAbS Therapeutics, Inc ,Merck & Co.Inc, Johnson & Johnson ,AstraZeneca, Bristol - Myers Squibb , Amgen Inc, GlaxoSmith Kline PLC.

Growth Forecast Projected:

The Global Brain Cancer Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Brain Cancer Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=brain-cancer-treatment-market?kb

Key Segments:

By Therapy: Immunotherapy, Immunotherapy, Targeted Therapy, Others

By Stages: Stage I, Stage II, Stage III, Stage IV

By Indication: Pituitary Tumor, Meningioma, Glioblastoma, Others

By Type: Primary brain cancer(benign), Secondary brain cancer(malignant)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Recent Drug Launches and Approvals

Jazz's Modeyso (fotemustine), approved by the FDA in 2025, is the first drug specifically approved for aggressive brain cancer types, offering clinicians a new chemotherapeutic tool with enhanced efficacy and tolerability.​

Vorasidenib, a targeted IDH1/2 mutant inhibitor by Agios, has shown promising Phase 3 results for low-grade gliomas, doubling progression-free survival and gaining FDA approval in 2024.​

Orbus Therapeutics released updated Phase 3 STELLAR clinical data for eflornithine plus lomustine demonstrating improved survival outcomes for recurrent grade 3 IDH-mutant astrocytoma.

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Brain Cancer Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Brain Cancer Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/brain-cancer-treatment-market?kb

Clinical Trial Advances

Neonc Technologies completed enrollment for a Phase 2a trial of NEO100, an intranasal plant-derived therapy showing tumor reduction in high-grade glioma patients, with some showing durable survival beyond typical prognosis.​

New CAR-T therapies developed in Switzerland demonstrated early success in destroying glioblastoma cells, potentially offering novel immunotherapeutic options for highly aggressive brain cancers.​

Several ongoing trials evaluate combination therapies, immunotherapies, and gene therapies aiming to improve overall survival and quality of life for brain cancer patients.

Get 2-Day Free Trial + 50% OFF DataM Subscription@: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.